Use of imatinib mesylate in CML patients autografted in the pre-imatinib mesylate era: A single center experience.

被引：0
|
作者：
Liesveld, JL [1 ]
Nichols, D [1 ]
Ifthikharuddin, JJ [1 ]
Lancet, JE [1 ]
Abboud, CN [1 ]
机构：
[1] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5471
引用
收藏
页码：473B / 473B
页数：1
相关论文
共 50 条
  • [21] BCR-ABL TYROSINE KINASE MUTATIONS IN IMATINIB MESYLATE RESISTANT CML PATIENTS FROM OMAN: SINGLE CENTRE EXPERIENCE
    Pathare, V.
    Alkindi, S.
    Al Zadjali, A.
    Al Farsi, S.
    Huneini, N.
    Zia, B.
    Dennison, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 576 - 576
  • [22] Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy
    Nilgun Karasu
    Hilal Akalin
    Nuriye Gokce
    Abdulbaki Yildirim
    Mikail Demir
    Hande Kulak
    Serhat Celik
    Muzaffer Keklik
    Munis Dundar
    Medical Oncology, 2021, 38
  • [23] Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate
    Simpson, E
    O'Brien, SG
    Reilly, JT
    CLINICAL AND LABORATORY HAEMATOLOGY, 2006, 28 (03): : 215 - 216
  • [24] Anti-leukemia immune responses in CML patients treated with imatinib mesylate.
    Chen, CIU
    Maecker, HT
    Neal, WH
    Falkow, R
    Lee, PP
    BLOOD, 2005, 106 (11) : 322A - 323A
  • [25] Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy
    Karasu, Nilgun
    Akalin, Hilal
    Gokce, Nuriye
    Yildirim, Abdulbaki
    Demir, Mikail
    Kulak, Hande
    Celik, Serhat
    Keklik, Muzaffer
    Dundar, Munis
    MEDICAL ONCOLOGY, 2021, 38 (10)
  • [26] Relationship between compliance, costs, hospitalizations for CML and GIST patients using imatinib mesylate
    Halpern, R.
    Barghout, V.
    Mody-Patel, N.
    Williams, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Imatinib mesylate as first line therapy in patients with Chronic Myeloid Leukemia (CML) - An experience from eastern India
    Dey, S.
    Mukhopadhyay, S.
    Gorai, K.
    Paul, C.
    Gupta, P.
    Choudhury, R.
    Ahmed, R.
    Mukhopadhyay, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 51 - 52
  • [28] Response to therapy with imatinib mesylate in patients with CML is poor in non-Caucasian patients.
    George, S
    Horvath, L
    Molokie, R
    Berry, J
    Rondelli, D
    Hoffman, R
    BLOOD, 2004, 104 (11) : 803A - 803A
  • [29] Molecular response rates achieved in chronic myelogenous leukemia (CML) patients treated with interferon, imatinib mesylate (STI) or stem cell transplantation.: A single institutional experience.
    Beksac, M
    Arat, M
    Dalva, K
    Ilhan, O
    Gürman, G
    Özcan, M
    Arslan, Ö
    Konuk, N
    Uysal, A
    Akan, H
    BLOOD, 2002, 100 (11) : 334B - 334B
  • [30] Imatinib mesylate (Glivec) preceding allogenic hematopoietic stem cell transplantation in Philadelphia-positive acute lymphoblastic leukemia: A single center experience.
    Tiribelli, M
    Marin, L
    Skert, C
    Candoni, A
    Sperotto, A
    Damiani, D
    Fanin, R
    BLOOD, 2003, 102 (11) : 230B - 230B
12345